Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
NCT ID: NCT03687294
Last Updated: 2020-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
70 participants
OBSERVATIONAL
2019-01-12
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Senstivity and Specificity of Using Salivary miRNAs in Detection of Malignant Transformation of Oral Lesions.
NCT04913545
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
NCT05730855
Validation of Salivary Proteomic Biomarkers for Early Detection of Oral Cancer in Egyptian Population
NCT06471270
Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions
NCT02323672
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
NCT06031337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
patients suffering from malignant salivary gland tumors.
enzyme linked immunosorbent assay (ELISA)
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Group II
patients suffering from benign salivary gland tumors.
enzyme linked immunosorbent assay (ELISA)
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
enzyme linked immunosorbent assay (ELISA)
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Benign tumors will be recruited in group II.
Exclusion Criteria
* Pregnant females.
* Subjects having any allergies, infectious or autoimmune diseases.
* Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yousra Refaey
pricipal investegator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Institute
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
yousrarefaey11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.